← Leaderboards
Maria De Los Angeles Lopez-Olivo
University Of Tx Md Anderson Can Ctr
$938,154
Attributed
$938,154
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $195.6K · FY2020–24$200K$150K$100K$50K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$938,154 · 1
By mechanism
K08$938,154 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Ahmed Kaseb$3,699,074
- Jonathan M Kurie$24,221,061
- John V. Heymach$11,138,593
- Joseph H McCarty$11,299,070
- Leland Hu$3,569,147
Others in their field
Other Emerging Leaders on “Adjuvant Therapy”
- Wendy Sammons-Jackson · National Institute Of Allergy And Infectious Diseases$10,000,000
- Jean Kwun · Duke University$5,686,708
- Patrick R Secor · University Of Montana$4,394,600
- Holly Rockweiler · Madorra, Inc.$4,300,000
- Kenneth B. Bader · University Of Chicago$4,178,329
- Alexandra Margaret Lynn Binder · University Of California Los Angeles$4,065,524
Research focus
Adjuvant TherapyAdverse EventAffectAutoimmune DiseasesBenefits And RisksBody SystemCancer PatientCancer RecurrenceCancer RiskCancer TherapyCareerCase SeriesCessation Of LifeCharacteristicsCheckpoint InhibitionChemotherapyChronicClinically RelevantClinical TrialsCognitiveComorbidityComplexConflict (Psychology)Ctla4 Gene
Grant awards (5)
Improving decision-making in patients with resectable melanoma and pre-existing autoimmune disease considering immune checkpoint inhibition$195,646
K08 · FY2024 · CA · contact PI
Improving decision-making in patients with resectable melanoma and pre-existing autoimmune disease considering immune checkpoint inhibition$191,520
K08 · FY2023 · CA · contact PI
Improving decision-making in patients with resectable melanoma and pre-existing autoimmune disease considering immune checkpoint inhibition$187,514
K08 · FY2022 · CA · contact PI
Improving decision-making in patients with resectable melanoma and pre-existing autoimmune disease considering immune checkpoint inhibition$183,625
K08 · FY2021 · CA · contact PI
Improving decision-making in patients with resectable melanoma and pre-existing autoimmune disease considering immune checkpoint inhibition$179,849
K08 · FY2020 · CA · contact PI